SuaRx RPh Solutions

New and exciting studies are coming out about additional therapeutic uses for GLP-1 agonists (Mounjaro, Ozempic, etc). The following medical data compilation, in particular, is mainly directed towards lowering the risk of Obesity-Related Cancers. Check out the gist of it.

SuaRx Summary:
A recent observational study presented at the 2025 ASCO Annual Meeting suggests that patients with diabetes and obesity who are treated with GLP-1 receptor agonists may have a modestly lower risk of developing obesity-related cancers compared with those treated with DPP-4 inhibitors.

Study Overview

The study analyzed data from 170,030 U.S. adults with:

A diagnosis of type 2 diabetes, and

A BMI ≥ 30, meeting the criteria for obesity.

Participants were divided evenly:

85,015 received a GLP-1 receptor agonist

85,015 received a DPP-4 inhibitor

The average participant was 56.8 years old with a mean BMI of 38.5.

Researchers examined the incidence of 14 obesity-related cancers as well as all-cause mortality.

Key Findings

Patients treated with GLP-1 receptor agonists experienced:

A 7% reduction in risk of any obesity-related cancer (aHR 0.93; P = .005)

An 8% reduction in all-cause mortality (aHR 0.92; P = .001)

There were 2,501 new cancer cases in the GLP-1 group versus 2,671 in the DPP-4 group.

Notably, GLP-1 therapy was associated with:

A 16% lower risk of colon cancer

A 28% lower risk of re**al cancer

Importantly, no increased risk was identified for any of the 14 cancer types examined.

Sex-Based Analysis

Outcomes differed by s*x:

Men: No meaningful association between medication type and cancer or mortality outcomes.

Women:

8% reduction in obesity-related cancer risk

20% reduction in all-cause mortality

Interpretation and Expert Opinion

While the study does not prove a causal relationship, it indicates that GLP-1 receptor agonists may offer additional health benefits beyond glucose control and weight reduction. Experts emphasize that more rigorous, controlled research is needed to confirm whether these medications can play a role in cancer prevention, including among individuals without diabetes.

BIG NEWS: SuaRx Is Now Offering NEW Services!

SRS is leveling up—and so are YOU. We’re rolling out powerful new services designed to boost pharmacy performance, drive growth, and simplify your day-to-day operations.

https://c.org/CWrfvyznYh

Sign the Petition Protect Independent Pharmacies in Miami

This campaign needs you now Protect Independent Pharmacies in Miami

https://gofund.me/3d2430fe

Donate to Wildfire Relief Fund 2025, organized by GoFundMe Org We are currently supporting relief and recovery efforts related to the wildfires burning in L.A… GoFundMe Org needs your support for Wildfire Relief Fund 2025